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Abstract
The influence of diameter on the pharmacokinetic and biodistribution of STEALTHR liposomes into the tumor (4T1 murine mammary
carcinoma) and cutaneous tissues (skin and paws) of mice was studied to ascertain the time course of liposome accumulation and to
determine if a preferential accumulation of liposomes into tumor over skin or paws could be achieved by altering liposome size. These tissues
were chosen as the dose-limiting toxicity for Caelyxk/DoxilR in humans is palmar-plantar erythrodysesthesia, a cutaneous toxicity. We
examined liposomes of four diameters: 82, 101, 154, or 241 nm. Liposomes with the three smallest diameters showed similar accumulation
profiles that were significantly higher than the largest liposomes in all three tissues of interest. We were unable to achieve a preferential
accumulation of liposomes into tumor over skin or paws based on size alone, as evidenced by the tumor to skin and tumor to paw ratios.
However, there were differences in the time courses of liposome accumulation in these three tissues. Liposome levels plateaued in tumors and
paws within 24 h, whereas skin levels plateaued between 24 and 48 h. The therapeutic activity of liposomal doxorubicin of three diameters
(100, 157, and 255 nm) was tested in the same model. All formulations delayed tumor growth, with liposomes of 100 or 157 nm being
equally efficacious and superior to liposomes of 255 nm.
D 2002 Elsevier Science B.V. All rights reserved.
Keywords: STEALTHR liposome; Biodistribution; Pharmacokinetics; Liposomal doxorubicin; Palmar-planter erythrodysesthesia
1. Introduction
Caelyx, STEALTHR liposomal doxorubicin (DoxilR in
the United States), has been approved for use in AIDS-
related Kaposi’s sarcoma and refractory ovarian cancer, and
is in clinical trials for other indications. In general, Caelyx
has shown good activity against a variety of solid tumors,
and its use has resulted in a reduction of doxorubicin-
associated side effects, including dose-limiting cardiac tox-
icity and myelosuppression, as well as other side effects like
alopecia, nausea, and vomiting [1–8]. The improved side
effect profile is a result of alterations in the pharmacoki-
netics and biodistribution of doxorubicin (DXR) that arise
when the drug is encapsulated within long-circulating
(STEALTHR) liposomes.
Despite the large body of literature on the pharmaco-
kinetics and biodistribution of STEALTHR liposomes,
there has been little experimental effort to study their
accumulation into cutaneous tissues, such as skin [9–11].
Furthermore, there have been no studies comparing the
accumulation of different sizes of liposomes into tumor
and cutaneous tissues, which is surprising given that the
dose-limiting toxicities of Caelyx are mucocutaneous
reactions such as stomatitis and palmar-plantar erythrody-
sesthesia [12]. Lokich and Moore [13] originally de-
scribed PPE for various anticancer agents, including
DXR, when given as prolonged infusions. Clinically, this
syndrome starts with paraesthesias, edema, and erythema,
and if left unchecked, can progress to blistering desqua-
mation, which requires discontinuation of the therapy
[12–14]. Histological evaluation of PPE lesions shows
areas of necrosis in the basal layers of the skin [12,14].
Areas of skin that are under pressure, such as flexure
creases on the hands, soles of the feet, or belt lines, are
particularly vulnerable [12].
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Dose reduction or delay has been used to prevent high-
grade PPE once lesions start to develop, and either of these
may have negative consequences on therapeutic outcome
[15]. Current interventions for PPE include patient counsel-
ing, oral pyridoxine, and topical dimethylsulfoxide which
partially relieve these symptoms [16–18]. A more complete
understanding of the factors that lead to the development of
PPE may lead to more efficacious strategies for its reduction
or elimination.
It is hypothesized that the long circulation time and small
size (100 nm diameter) of Caelyx allow the liposomes to
extravasate in pressure areas and/or micro-traumatized areas
in the skin, where they accumulate and release DXR over
several days or weeks [12]. This is thought to damage cells
in the basal layers of the skin, resulting in PPE. This
hypothesis is supported by current clinical data; the plasma
half-life (t1/2) of Caelyx is approximately 48 h in humans,
which mimics a prolonged infusion [19]. Indeed, a recent
study demonstrated that the development of PPE correlated
with the plasma t1/2 of DXR in patients with metastatic
breast cancer [20]. There is also a relationship between the
development of PPE and the dose intensity of Caelyx
therapy, with an increased incidence (up to 40% in one
study of patients treated for ovarian cancer) occurring
in patients receiving greater than 10–12 mg/m2/week
[2,3,12,21,22]. Further evidence to support this hypothesis
is that a different liposomal formulation of DXR, Myocetk,
does not produce PPE and has a different dose-limiting
toxicity (leukopenia). Myocet is larger then Caelyx (160
versus 100 nm), has a substantially shorter half-life in
humans (approximately 7 h), and has a much more rapid
rate of drug release, as evidenced by its significantly larger
volume of distribution [23].
Altering the size of liposomes can lead to changes in
their biodistribution. Thus, it may be possible to reduce skin
accumulation of liposomes without compromising tumor
accumulation by increasing liposomal mean diameter. To
test this hypothesis, we examined the accumulation of
STEALTHR liposomes into tumor, skin, and paws in
relation to their mean diameter and time after injection in
a murine mammary carcinoma model. The goals of the
study were to ascertain the time course of liposome accu-
mulation into these tissues and to determine if it is possible
to achieve a differential accumulation of liposomes into
tumor relative to skin and/or paws, based solely on changes
in the diameter of the liposomes. The rationale for this is
that tumors have a defective endothelium with gaps between
the cells in the range of 380–780 nm, rendering the tumors
permeable to appropriate diameters of liposomes and macro-
molecules [24,25]. Because the biodistribution of liposomes
is size dependent [26,27], an increase in diameter (e.g.,
150–250 nm versus the 100 nm of Caelyx) may reduce
liposome accumulation in normal tissues (i.e., skin) without
having substantial effects on tumor uptake. In addition to
biodistribution experiments, we also performed therapeutic
experiments in the same tumor model, using DXR-loaded
STEALTHR liposomes of various diameters, to determine
the therapeutic significance of any size-dependent alterna-
tions in tissue distribution.
2. Materials and methods
2.1. Materials
Hydrogenated soy phosphatidylcholine (HSPC), me-
thoxypolyethyeneglycol (Mr 2000)-distearoylphosphatidy-
lethanolamine (mPEG2000-DSPE) and doxorubicin hy-
drochloride (DXR) were donated by ALZA Corporation
(Mountain View, CA). Cholesterol was purchased from
Avanti Polar Lipids (Alabaster, AL). Sephadex-G50 and
Sepharose CL-4B were from Amersham-Pharmacia Biotech
(Baie d’Urfe, PQ, Canada). Minimal essential medium
(MEM) was from Sigma (St. Louis, MO). Fetal bovine
serum (FBS), penicillin, and streptomycin were from Life
Technologies (Burlington, ON, Canada). Sterile, pyrogen-
free saline was purchased from Baxter (Toronto, ON,
Canada) and was supplemented with 25 mM 4-(2-hydrox-
yethyl)-1-piperazineethanesulfonic acid, pH 7.4 (HEPES-
buffered saline). Na125I was purchased from Amersham
(Oakville, ON, Canada) and 125I-tryaminylinulin (125I-TI;
an aqueous space marker for liposomes) was prepared as
previously described [28]. All other chemicals were of the
highest grade possible.
2.2. Liposome preparation
All liposomes were composed of HSPC:CHOL:m-
PEG2000-DSPE (3:1:1 w/w). For biodistribution experi-
ments, liposomes were prepared by hydrating dried lipid
films with HEPES-buffered saline (HBS) containing 125I-TI.
Liposomes were sized by sequential extrusion through
stacked Nuclepore polycarbonate filters (0.4 Am down to
0.080 Am) using an extrusion device (Lipex Biomem-
branes, Vancouver, BC, Canada) at 65 jC and had low
polydispersities. Free 125I-TI was separated from liposome-
encapsulated 125I-TI by size exclusion chromatography on
a Sepharose CL-4B column eluted with HBS. For thera-
peutic experiments, DXR was remote loaded with an
ammonium sulfate gradient as previously described [29].
Briefly, lipid films were hydrated in 250 mM ammonium
sulfate and preparations with low polydispersity were made
by extrusion through Nuclepore filters with appropriate
pore sizes. The external buffer was changed to sodium
acetate (pH 5.5) by passage over a Sephadex G-50 column,
and then DXR, dissolved in 10% sucrose (w/v), was
incubated with the liposomes at a 0.2:1 (w) drug/lipid ratio
for 15 min at 65 jC. Unencapsulated DXR was separated
by passage over a Sephadex G-50 column equilibrated with
HBS, pH 7.4.
Liposomes were sized by dynamic light scattering using
a Brookhaven BI-90 particle sizer (Brookhaven Instruments,
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Holtsville, NY). DXR concentrations were determined from
a standard curve in methanol extracts at 480 nm; phospho-
lipid concentrations were determined by the method of
Bartlett [30].
2.3. Animal experiments
Female BALB/c mice (6–8 weeks) were purchased
from the breeding colony at Health Sciences Laboratory
Animal Services. Mice were housed under standard con-
ditions and had access to food and water ad libitum. All
protocols were in accordance with the Guide to the Care
and Use of Experimental Animals set forth by the Cana-
dian Council on Animal Care and approved by the Health
Sciences Animal Policy and Welfare Committee, University
of Alberta.
2.4. Tumor cell lines and tumor implantation
The 4T1 mouse mammary carcinoma cell line, a meta-
static, thioguanine-resistant cell line, was donated by Dr.
Fred Miller (Barbara Ann Karmanlos Cancer Institute,
Detroit, MI) [31]. The cell line was maintained in MEM
supplemented with 10% FBS, penicillin (100 units/ml), and
streptomycin (100 Ag/ml) at 37 jC in a humidified incubator
with a 5% CO2 atmosphere. Cells were harvested for
passage with the use of phosphate-buffered saline contain-
ing EDTA (PBS-EDTA; 0.54 mM EDTA, 137 mM NaCl, 3
mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4)
followed by trypsin EDTA (0.05% trypsin in 137 mM NaCl,
5.4 mM KCl, 7 mM NaHCO3, 0.34 mM EDTA).
Tumors were implanted as previously described [32].
Briefly, female BALB/c mice were anesthetized with
methoxyflurane (Metafane, Janssen, Toronto, ON, Canada).
A 6- to 8-mm incision was made adjacent to the mid-line in
the lower abdominal region to expose the right #4 mammary
fat pad where 105 4T1 cells were injected in 10 Al of full
media. The incision was then closed with a surgical wound
clip, which was removed 7 days later.
2.5. Biodistribution studies
Female BALB/c mice were implanted with the 4T1
mammary carcinoma as described above. Ten days after
tumor inoculation, when tumors were well developed, mice
were injected intravenously with 200 Al HBS containing 0.5
Amol of 125I-TI-labeled liposomes (1.5–2.5 105 cpm per
mouse) with mean diameters (polydispersity) of 82 (0.111),
101 (0.122), 154 (0.073), or 241 (0.081) nm. At 24, 48, 72,
or 96 h after injection, groups of 10 mice were euthanized,
and organs (tumor, skin, and paws) were taken for radio-
active counting (Beckman 8000 gamma counter). The skin
was washed and shaved to remove hair and contaminating
blood, and data from all four paws were pooled. Results are
expressed as cpm per mg tissue normalized to 106 injected
cpm. The data were corrected for the blood volume of
organs as previously described [33]. Tumor to skin and
tumor to paw ratios were calculated from the data. A one-
way ANOVAwith a Tukey–Krammer post test was used for
all statistical comparisons using Graph Pad InStat version
3.01 for Windows 95/NT (GraphPad Software, San Diego
CA).
2.6. Therapeutic studies
Groups of five mice were implanted with the 4T1 tumor
as previously described. Four days after tumor implantation,
mice were injected intravenously with liposomal DXR (6
mg/kg) of various diameters (polydispersity): 102 (0.152),
156 (0.077), or 254 (0.086) nm. The 4T1 tumor grows
rapidly; therefore, therapeutic experiments were started 4
days after tumor implantation when the tumors were just
palpable, even though biodistribution experiments were
carried out 10 days after tumor implantation, when the
tumors were large enough to excise. Tumor blood content,
measured using 111In-labeled murine red blood cells,
showed that tumor blood content was proportional to tumor
weight and volume (data not shown). Liposomes of 82 nm
diameter were not used for the therapeutic studies because
their pharmacokinetics and biodistribution was similar to the
101-nm liposomes. Tumor growth was monitored by meas-
uring perpendicular diameters (a and b), and volume was
calculated with the formula v = 0.4ab2, where b>a. The
experiment was repeated once with liposomes having sim-
ilar mean diameters (polydispersity): 98 (0.140), 159
(0.078), or 256 (0.054) nm. The results at each liposome
size were pooled as follows: 100 nm (98 and 102 nm), 157
nm (156 and 159 nm), and 255 nm (254 and 256 nm). All
control mice received 200 Al of sterile saline. Results are
presented as the meanF S.D. with n = 6–10. There were no
statistically significant differences between the end tumor
volumes of the replicates as determined by a one-way
ANOVA.
3. Results
3.1. Biodistribution experiments
Tumor uptake of 125I-TI liposomes is shown in Fig. 1A.
Tumor accumulation of liposomes was highest at 24 h for
all sizes tested. The largest liposomes (241 nm) had
substantially lower tumor levels than the smaller sizes at
all time points (P < 0.001). Some statistically significant
differences also occurred among the tumor uptakes of the
smaller liposomes, although these may not be therapeuti-
cally significant (see results of therapeutic experiments
below). For example, the 101-nm liposomes had higher
accumulation in tumor than the 82-nm liposomes at 24 and
48 h after injection (P < 0.05–0.01) and had significantly
higher accumulation than the 154-nm liposomes at all time
points (P < 0.05–0.001). Also, the 82-nm liposomes had
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higher tumor levels than the 154-nm liposomes at 72 and
96 h after injection (P < 0.05 and P < 0.001).
Results of the uptake of liposomes into paws are shown
in Fig. 1B. Liposome levels in paws were significantly
lower than tumor levels. Except for the 241-nm liposomes,
the level of liposomes in paws was highest at 48 h. The
largest (241 nm) liposomes attained lower levels in paws
than the smaller sizes of liposomes (P < 0.01 to P < 0.001).
Other statistically significant differences between the paw
uptake of the other liposomes were as follows: the 101-nm
liposomes had higher paw accumulation than the 154-nm
liposomes at all time points (P < 0.01 to P < 0.001) and had
higher accumulation than the 82-nm liposomes at 24, 48,
and 72 h (P < 0.05 to P < 0.01). The 82-nm liposomes had
higher paw levels at 72 and 96 h than the 154-nm liposomes
(P < 0.001).
Skin accumulation of liposomes is shown in Fig. 1C.
Skin levels of liposomes were significantly lower than
tumor levels, and, with a few exceptions (154 nm at 24
h, 101 nm at 48 h, and 82 nm at 96 h), were also sig-
nificantly lower than paw levels (P < 0.05 to P < 0.001).
Skin levels of the largest liposomes were highest at 24 h
after injection, whereas the smaller sizes had peak levels at
48 h. For the 48-, 72-, and 96-h time points, the largest
liposomes had significantly lower skin accumulation than
the smaller liposomes (P < 0.01 to P < 0.001). Again these
data show that the three smaller sizes of liposomes accu-
mulate to a greater extent in tissue than the largest size of
liposomes.
Blood levels of liposomes are presented in Fig. 1D. The
blood concentrations of the two smallest liposomes (82 and
101 nm) were similar, and were significantly higher than
blood concentrations for the 254-nm liposomes at all time
points (P < 0.05–0.001) or the 154-nm liposomes, except
at 96 h (P < 0.01–0.001). The 154-nm liposomes achieved
higher blood levels that the largest liposomes for the 24-,
48- and 96-h samples (P < 0.001). These blood levels are
consistent with other data showing that liposomal diameter
influences circulation times [34].
Tumor to paw ratios are presented in Table 1A. There
were no significant differences within the data columns, that
is, altering liposome size did not produce a preferential
accumulation of liposomes into tumor versus paws. How-
ever, for a given size of liposome, the tumor to paw ratios
decreased significantly over time. At 24 h after injection,
regardless of liposome size, almost four times as many
liposomes accumulated in tumor than in paws and this
decreased to approximately two-fold by 96 h after injection
Fig. 1. Accumulation of 125I-tyraminylinulin liposomes in mouse tissues as a function of time. BALB/c mice were implanted in the #4 mammary fat pad with
the 4T1 tumor and injected IV 10 days later with 125I-tyraminylinulin-labelled liposomes of various mean diameters: ., 82 nm;E, 101 nm; n, 154 nm; x, 241
nm. Data are expressed as cpm/mg tissue normalized to 106 cpm injected. (A) 4T1 mouse mammary carcinomas, (B) mouse paws, (C) skin, (D) blood. Data
represent the meanF S.D., n= 10. See text for results of statistical comparisons.
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(P < 0.01). The ratios at the 24-h time point for all liposome
diameters were significantly higher than the other time
points (P < 0.05 to P < 0.001).
Tumor to skin ratios are presented in Table 1B. At the 24-
h time point, only the 101-nm liposomes had a significantly
higher ratio than the three sizes of liposomes. (P < 0.01 to
P < 0.001). There were no other significant differences in the
tumor to skin ratios for the different sizes of liposomes at all
other time points. However, for any given size of liposome,
the tumor to skin ratios decreased over time. The three
smaller liposome sizes had approximately 8- to 17-fold
higher levels in tumor than in skin at 24 h and this decreased
significantly with time to approximately 3- to 4-fold by 96 h
after injection (P < 0.01 to 0.001). The tumor to skin ratios
for the largest liposomes (241 nm) also decreased over time,
with the ratio at 24 h being significantly higher than the ratio
at 96 h (P < 0.01).
3.2. Therapeutic experiments
All three tested sizes of liposomal DXR delayed tumor
growth (Fig. 2). The smaller liposomes (100 and 157 nm)
had almost equivalent anticancer activity, which was greater
than that seen for the larger liposomes (255 nm). These data
are consistent with data from the biodistribution experi-
ments, which showed greater tumor accumulation of the
smaller liposomes compared with the largest ones. It is
reasonable to expect that higher tumor levels of drug for the
smaller liposomes would result in greater therapeutic activ-
ity. The small differences seen in the level of tumor
accumulation for the smaller liposomes (101 and 154 nm),
although statistically significant, resulted in no measurable
differences in therapeutic activity.
4. Discussion
The biodistribution of STEALTHR liposomes has long
been known to be size dependent, and the dermal local-
ization of long-circulating liposomes has been previously
described [9,11,27,35,36]. However, this is the first system-
atic investigation to compare the accumulation of liposomes
in tumors versus cutaneous tissues (skin and paws). Results
of this study indicate that time to peak levels of liposome
accumulation was delayed in cutaneous tissues relative to
tumor tissue, and time to peak levels was not dependent on
liposome size.
Liposome levels peaked in tumor tissue at or before 24 h,
whereas levels in skin and paws peaked at 48 h. If a
liposome system can be engineered that leaks its drug
contents after tumor levels peak, but before skin levels
peak, it might lead to lower levels of drug in the skin,
potentially reducing the likelihood of PPE. The higher
uptake of liposomes into paws compared to skin suggests
that there may be a pressure-dependent extravasation of
liposomes into paws. Pressure would be exerted on the paws
as the mice walk around the cage, feed, groom, etc.
Although we did not apply external pressure on the mice’s
skin to mimic human skin under pressure (e.g., belt lines),
our paw data may reflect the human condition where PPE
lesions are found on the hands and feet. Thus, following the
clinical administration of long-circulating liposomal DXR, it
may be necessary to limit activity to avoid this pressure-
dependent accumulation of liposomes. Indeed, some clini-
cians prescribe bed rest for patients on Caelyx therapy for a
short period of time following drug administration. Addi-
Fig. 2. Therapeutic activity of various sizes of STEALTHR liposomal
doxorubicin against the 4T1 mouse mammary carcinoma. BALB/c mice
were implanted with the #4 mammary fat pad with the 4T1 tumor and 4
days later (arrow) were treated with STEALTHR liposomal doxorubicin of
various mean diameters: ., saline control;E, 100 nm; n, 157 nm; x, 255
nm. The results represent the meanF S.D. of 6–10 mice from two pooled
experiments.
Table 1B
Tumor to skin ratios as a function of time after injection
24 h 48 h 72 h 96 h
82 nm 8.8F 2.3 4.5F 1.2 4.0F 1.6 3.3F 1.1
101 nm 17.0F 9.6 5.9F 2.2 5.1F1.9 3.7F 1.3
154 nm 8.4F 3.2 4.8F 1.9 4.1F1.0 4.1F 0.7
241 nm 6.3F 2.6 5.5F 1.4 5.0F 1.8 3.6F 1.1
Data represent the ratios of liposome levels in tumor and skin (cpm/mg
tissue) for the meanF S.D. of 10 mice. Ratios were calculated from the data
in Fig. 1A and C.
Table 1A
Tumor to paw ratios as a function of time after injection
24 h 48 h 72 h 96 h
82 nm 3.6F 0.5 2.6F 0.4 2.8F 0.7 2.3F 0.5
101 nm 3.7F 0.9 3.0F 1.2 2.6F 0.8 2.1F 0.6
154 nm 3.6F 1.4 2.8F 0.5 2.5F 0.5 2.3F 0.6
241 nm 3.3F 1.0 2.5F 0.7 2.1F 0.8 2.0F 0.4
Data represent the ratios of liposome levels in tumor to paw (cpm/mg
tissue) for the meanF S.D. of 10 mice. Ratios were calculated from the data
in Fig. 1A and B.
G.J.R. Charrois, T.M. Allen / Biochimica et Biophysica Acta 1609 (2003) 102–108106
tionally, patients on Caelyx are counseled to avoid situations
that will increase blood flow to the skin (e.g., hot baths) in
an effort to reduce the number of liposomes localizing in the
skin.
Tumor to skin and tumor to paw ratios did not change
for the various sizes of liposomes. This demonstrates that
altering liposome diameter does not decrease liposome
accumulation into skin or paws without a proportional
decrease in tumor accumulation. This is a surprising
finding given that tumor blood vessels are reported to
be leakier than normal capillaries (skin and paws), due to
fenestrations and gaps in the endothelium that can range
in size from 380 to 780 nm [25,37]. This would suggest
that even though there are large gaps in the tumor
vasculature, there is also a size cutoff for particles that
can pass through these gaps. Recent work by Hobbs et al.
[25] demonstrated that the pore sizes in tumor blood
vessels were dependent upon the tumor model used and
on the anatomical location of tumor implantation. Most
tumors implanted subcutaneously exhibited a pore size
range of 380–780 nm (as large as 1.2–2 Am in one
tumor type); pore size was smaller in the cranial micro-
environment. The authors also identified that pore size
range is heterogeneous in any given tumor, and that, for a
particle or liposome to penetrate the pore, its diameter
should be much smaller than that of the pore. Because
pore size is dependent upon tumor type and location,
using a ‘‘leakier’’ tumor may have produced a difference
in the tumor to skin ratios for the various sizes of
liposomes. Ishida et al. further demonstrated the concept
of pore size cutoff in recent experiments with the murine
C26 colon carcinoma implanted subcutaneously. The
authors showed a size-dependent accumulation of
STEALTHR liposomes that was independent of blood
liposome concentrations [34]. This was inferred from
the observation that increasing the blood levels of 400-
nm-diameter STEALTHR liposomes (achieved following
splenectomy) did not increase liposome accumulation into
tumors. In other words, the odds of any particle passing
through a pore increases as the particle size decreases
relative to the diameter of the pore.
In the current study, we hypothesize that the 4T1 tumor
may have a pore size cutoff of approximately 250 nm, as
liposome accumulation dropped off significantly for the
largest size of liposomes. Skin and paws accumulated
substantially lower concentrations of liposomes than did
tumors, but tumors also exhibited a similar fall-off in
accumulation for the larger liposomes. The lower levels of
liposome accumulation in skin and paws are consistent with
the explanation that blood vessels in these tissues are
‘‘tighter’’ than those found in solid tumors.
The data from the therapeutic experiments show a depend-
ence of therapeutic activity on liposome size, with smaller
liposomes (100 and 157 nm) being more efficacious than
larger liposomes (255 nm). This is probably due to higher
tumor levels of the smaller liposomes, and is consistent with
work from other laboratories using doxorubicin or annamy-
cin [38,39]. Although the 100-nm size of Caelyx is consid-
ered optimal for therapeutic activity, based on our data, a
modest increase in size would probably not result in a
decrease in therapeutic activity and may also not reduce the
incidence of cutaneous toxicities such as PPE. However, a
small increase to 150 nm would result in higher drug to lipid
ratios, which may offer a cost saving in liposome preparation.
Several factors are likely responsible for the decrease
over time in tumor to skin and tumor to paw ratios. First, the
concentrations of liposomes in skin and paws peak later than
that in tumors. As skin and paw concentrations increase,
their ratios to tumor concentrations will decrease if they are
accumulating liposomes to a greater degree than tumors at
later time points. Secondly, tumors continue to grow over
the course of the study, with weights ranging from 0.20 g at
24 h after injection to 0.34 g at 96 h after injection. If the
tumor grows faster than the rate of accumulation of lip-
osomes in the tumor, the concentration of liposomes (cpm
per mg tissue) will decrease.
This study provides some guidance into potential strat-
egies that may be used to avoid PPE. The increased
accumulation of liposomes into paws over skin may reflect
a pressure-dependent extravasation of liposomes, suggesting
that bed rest and a reduction in daily activities may help to
reduce PPE in the hands and feet. These findings provide a
potential strategy to reduce the incidence of PPE, for
example, by engineering liposome formulations that allows
for the release of drug from liposomes after maximal tumor
accumulation occurs, but before skin levels plateau, either
by altering drug leakage rates or triggering drug release
(e.g., hyperthermia or programmable fusogenic vesicles)
[40–42]. Ongoing experiments are being conducted to test
this hypothesis.
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